Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Malignancy risk in systemic lupus erythematosus (SLE) is about 15% higher than the general age-and-sex-matched population. Hematologic cancers, especially B-cell lymphomas, are about three-fold ...

Background SLE is an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which among QRISK2, QRISK3, Framingham Risk Score (FRS), modified Framingham Risk Score ...

Objective To investigate the role of curcumin in the treatment of lupus nephritis (LN) by inhibiting the migration of neutrophils and the underlying mechanism involved. Methods Two lupus mouse models, ...

Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, ...

Objective Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the ...

Objectives To measure the expression level of the vacuolar protein sorting 13 (VPS13) gene and stimulator of interferon genes (STING) in patients with SLE with and without reported neuropsychiatric ...

Objectives To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. Methods A post hoc analysis was conducted using pooled data from phase III, randomised ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Background The course and evolution of the SLE depends on the affected organ, adherence to treatment and accumulated organ damage, but ethnicity plays a fundamental role, leading to worse results in ...